NanoViricides measles drug development animal study imminent

NanoViricides (NNVC) announced it is forging ahead with its Measles drug development program. The company has commissioned an animal trial to evaluate certain drug candidates, including NV-387, in a lethal animal infection model using specially modified mice. The study will initiate as soon as the animals arrive and are acclimatized. President and Executive Chairman Anil Diwan stated confidence in NV-387’s activity against Measles virus, noting it cured lethal RSV infection in animals. There is no approved drug for Measles infection.